According to the 2024 National Comprehensive Cancer Network (NCCN) guidelines, molecular testing is recommended for all NSCLC patients to detect EGFR and BRAF mutations, ALK and ROS1 rearrangements, and PD‐L1 expression, without exception based on clinical characteristics. Here, ALK is linked to non-small cell lung carcinoma.